statistiche ricercatore

Continente	#
NA - Nord America	759
AS - Asia	500
EU - Europa	304
SA - Sud America	83
Continente sconosciuto - Info sul continente non disponibili	30
AF - Africa	28
Totale	1.704

Nazione	#
US - Stati Uniti d'America	702
SG - Singapore	167
IT - Italia	136
CN - Cina	106
VN - Vietnam	79
BR - Brasile	53
DE - Germania	49
HK - Hong Kong	43
CA - Canada	32
IN - India	32
FI - Finlandia	20
GB - Regno Unito	19
JP - Giappone	17
ZA - Sudafrica	17
BD - Bangladesh	15
FR - Francia	14
ID - Indonesia	12
RU - Federazione Russa	11
PL - Polonia	9
AR - Argentina	8
MX - Messico	8
UA - Ucraina	8
SE - Svezia	7
PE - Perù	6
TR - Turchia	6
CH - Svizzera	5
CZ - Repubblica Ceca	5
EC - Ecuador	5
NL - Olanda	5
IL - Israele	4
VE - Venezuela	4
DZ - Algeria	3
ES - Italia	3
IQ - Iraq	3
KE - Kenya	3
PR - Porto Rico	3
PT - Portogallo	3
TT - Trinidad e Tobago	3
CL - Cile	2
CO - Colombia	2
CR - Costa Rica	2
CW - ???statistics.table.value.countryCode.CW???	2
GA - Gabon	2
HN - Honduras	2
IE - Irlanda	2
JM - Giamaica	2
KG - Kirghizistan	2
KR - Corea	2
NP - Nepal	2
PA - Panama	2
PH - Filippine	2
AL - Albania	1
AT - Austria	1
AZ - Azerbaigian	1
BE - Belgio	1
BJ - Benin	1
BO - Bolivia	1
ET - Etiopia	1
GP - Guadalupe	1
GR - Grecia	1
JO - Giordania	1
KH - Cambogia	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
LU - Lussemburgo	1
LV - Lettonia	1
MY - Malesia	1
NI - Nicaragua	1
OM - Oman	1
PK - Pakistan	1
PY - Paraguay	1
RO - Romania	1
SV - El Salvador	1
TN - Tunisia	1
TW - Taiwan	1
UY - Uruguay	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.677

Nome	#
An engineered factor X variant as a novel by-passing agent for hemophilia	191
Counteracting the Common Shwachman-Diamond Syndrome-Causing SBDS c.258+2T>C Mutation by RNA Therapeutics and Base/Prime Editing	173
OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies	169
Addressing pathogenic splicing mutations through RNA therapeutics and DNA editing approaches	168
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia	155
Deep molecular mechanisms of F8 exon 19 variants and translational approaches in Hemophilia A	136
Rescue of a FVIII splicing variant with engineered U1snRNAs	107
Rescue of a panel of Hemophilia A-causing 5’ss splicing mutations by unique Exon-specific U1snRNA variants	102
A 5’ SPLICE-SITE MUTATION CAUSING MUCOLIPIDOSIS TYPE III CAN BE EFFICIENTLY RESCUED BY U1 SNRNA-BASED THERAPY	101
Rescue of an F8 splicing variant (c.1752+5 G>C) with engineered U1snRNAs	93
Rescue of a panel of splicing mutations causing hemophilia A by engineered U1snRNAs	93
Rescue of a hemophilia A-causing FVIII splicing variant via engineered U1SNRNAS	89
Prime editing of the common Familial Dysautonomia-causing c.2204+6T>C splicing mutation	67
RESCUE OF A PANEL OF SPLICING MUTATIONS CAUSING HEMOPHILIA A BY ENGINEERED U1-SNRNAS	60
Totale	1.704

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	14	0	0	0	0	1	3	0	2	2	0	0	6
2022/2023	36	2	2	1	1	3	2	12	2	4	0	6	1
2023/2024	60	5	6	6	2	2	14	6	4	3	1	1	10
2024/2025	329	12	9	21	12	26	36	7	21	50	37	43	55
2025/2026	942	120	50	75	97	121	65	100	49	85	106	52	22
2026/2027	322	30	83	95	94	20	0	0	0	0	0	0	0
Totale													1.704

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara